Cargando…

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC). Biomarkers relevant to the antitumor effects of IL-2 that may be altered by sorafenib including the perc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monk, Paul, Lam, Elaine, Mortazavi, Amir, Kendra, Kari, Lesinski, Gregory B., Mace, Thomas A., Geyer, Susan, Carson, William E., Tahiri, Sanaa, Bhinder, Arvinder, Clinton, Steven K., Olencki, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966917/ https://www.ncbi.nlm.nih.gov/pubmed/24598448 http://dx.doi.org/10.1097/CJI.0000000000000023

Ejemplares similares

Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients
por: Farren, Matthew R, et al.
Publicado: (2015)

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2019)

Long-Term Survivors with Metastatic Uveal Melanoma
por: Buzzacco, Dominic M, et al.
Publicado: (2012)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy
por: Singh, Priyamvada, et al.
Publicado: (2019)

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma
por: Lam, Elaine T., et al.
Publicado: (2014)

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
por: Ott, Patrick A., et al.
Publicado: (2010)

Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment
por: Mace, Thomas A, et al.
Publicado: (2013)

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
por: Pécuchet, N, et al.
Publicado: (2012)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma: The role of Arginase 2 in sorafenib-induced ferroptosis in melanoma
por: Yu, Yi, et al.
Publicado: (2022)

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
por: Bhatia, Shailender, et al.
Publicado: (2014)

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
por: Rossfeld, Kara, et al.
Publicado: (2017)

MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
por: Markowitz, Joseph, et al.
Publicado: (2016)

Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells
por: Cao, J.Y., et al.
Publicado: (2017)

Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
por: Pal, Harish C., et al.
Publicado: (2015)

Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function
por: Mace, Thomas A., et al.
Publicado: (2019)

Interleukin 32 expression in human melanoma
por: Paz, Helicia, et al.
Publicado: (2019)

Interleukins in the treatment of melanoma
por: Xu, Xinyuan, et al.
Publicado: (2022)

Single-agent interleukin-2 in the treatment of metastatic melanoma
por: Petrella, T., et al.
Publicado: (2007)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells
por: Lesinski, Gregory B, et al.
Publicado: (2010)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

Clear-Cell Sarcoma With an Unusual Presentation Mimicking Metastatic Melanoma
por: Tahiri Elousrouti, Layla, et al.
Publicado: (2022)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
por: Eisen, T, et al.
Publicado: (2006)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma
por: Farren, Matthew R, et al.
Publicado: (2015)

Stabilization of metastatic myxopapillary ependymoma with sorafenib
por: Fegerl, Gundula, et al.
Publicado: (2012)

Robust tumor immunity to melanoma mediated by interleukin 9
por: Purwar, Rahul, et al.
Publicado: (2012)

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
por: Mouriaux, F, et al.
Publicado: (2016)

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients
por: Tarabadkar, Erica S., et al.
Publicado: (2018)

Expression of interleukin 10 in human melanoma.
por: Krüger-Krasagakes, S., et al.
Publicado: (1994)

Antitumor Activities of Interleukin-12 in Melanoma
por: Gao, Wei, et al.
Publicado: (2022)

Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3
por: Zhuang, Pengyuan, et al.
Publicado: (2023)

Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines
por: Bill, Matthew A., et al.
Publicado: (2012)

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin
por: Xia, Yun, et al.
Publicado: (2016)

Effective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stress
por: Antunes, Fernanda, et al.
Publicado: (2020)

Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
por: Panetta, John C., et al.
Publicado: (2021)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_teqg1ra3k2mcl04sb8fjal6hs4